within 2 years of biochemical recurrence. Additionally, consistent with other studies examining biochemical outcome after salvage RT, the survival benefit in this study cohort was seen only among men whose PSA became undetectable after salvage RT. 9
Search Results
Matthew E. Nielsen, Bruce J. Trock, and Patrick C. Walsh
Bin-Yi Xiao, Xuan Zhang, Tai-Yuan Cao, Dan-Dan Li, Wu Jiang, Ling-Heng Kong, Jing-Hua Tang, Kai Han, Chen-Zhi Zhang, Wei-Jian Mei, Jian Xiao, Zhi-Zhong Pan, Yun-Feng Li, Xiao-Shi Zhang, and Pei-Rong Ding
unresectable, and 3 refused surgery for unspecified reasons. Outcomes of Patients With Locally Advanced (cT4a/4b) Disease A total of 48 patients had locally advanced disease, with CR and PR observed in 4 (8.3%) and 37 (77.1%) of them, respectively; the
Yajun Zhu, Yimei Han, Naleen Raj Bhandari, and Lisa Hess
Objectives: This study identified factors associated with genomic biomarker testing (“tested” vs “not tested”) and examined the association of the receipt of treatment that is guided by genomic biomarker testing results with survival outcomes among
Scott Paulson, Curtis Waycaster, Bismark Baidoo, Astra M. Liepa, Anindya Chatterjee, and Lisa M. Hess
Background: It is generally assumed that adherence to clinical practice guidelines can reduce treatment variability and improve patient outcomes. Gastric cancer clinical treatment pathways were implemented in the US Oncology Network (USON) in
Ashley Tabah, David Huggar, Ronda Copher, Marc Tian, and Ali McBride
real-world treatment patterns and outcomes in metastatic NSCLC patients treated with a first line (1L) therapy. Methods: A retrospective cohort analysis of IBM MarketScan@ Commercial and Medicare Supplemental Claims Databases was conducted. The
David Miller, Roberto Palencia, Ting Yu, Amrita Sandhu, Sarah Webb, Tom Blaikie, and Murtuza Bharmal
studies with efficacy and safety outcomes with relevant interventions in patients with stage I-III MCC. The review included monotherapies or combinations of pharmacological treatments, radiotherapy (RT), chemotherapy (CT), and surgery (SUR). Adjuvant (adj
Kajal Patel, Soham Shukla, Jennifer Hanlon, Kelly Bell, Laurie Eliason, and Cosmina Hogea
-reported outcome (PRO) data, an important resource in the field of oncology, has the potential to offer direct insight into the patient’s treatment experience, beyond efficacy and safety measures. Methods: A targeted literature search for PROs was performed using
George D. Demetri, Robert S. Benjamin, Charles D. Blanke, Jean-Yves Blay, Paolo Casali, Haesun Choi, Christopher L. Corless, Maria Debiec-Rychter, Ronald P. DeMatteo, David S. Ettinger, George A. Fisher, Christopher D. M. Fletcher, Alessandro Gronchi, Peter Hohenberger, Miranda Hughes, Heikki Joensuu, Ian Judson, Axel Le Cesne, Robert G. Maki, Michael Morse, Alberto S. Pappo, Peter W. T. Pisters, Chandrajit P. Raut, Peter Reichardt, Douglas S. Tyler, Annick D. Van den Abbeele, Margaret von Mehren, Jeffrey D. Wayne, and John Zalcberg
worse outcome than tumors with other KIT or PDGFRA mutant isoforms or with no detectable mutation. 31 – 34 Conversely, KIT exon 11 mutations have been found in mitotically inactive GISTs 1 cm or less in size, suggesting that oncogenic KIT activity
Zhuoran Tang, Chunyu Li, Peixin Chen, Haoyue Guo, Jinpeng Shi, Yingying Pan, Qi Wang, and Caicun Zhou
characteristics. The risk score was determined using LASSO Cox regression analysis. Meanwhile, we named this risk score as “TANlncSig”. TANlncSig was able to distinguish between better and worse survival outcomes in various patient datasets independently of other
Apostolia M. Tsimberidou, Alexandra M. Adamopoulos, Yang Ye, Sarina Piha-Paul, Filip Janku, Siqing Fu, David Hong, Gerald S. Falchook, Aung Naing, Jennifer Wheler, Adoneca Fortier, Razelle Kurzrock, and Kenneth R. Hess
study, which reported that the most common toxicities were myelosuppression and gastrointestinal adverse effects. 15 Table 4 Clinical Outcomes by Tumor Type Taking into consideration that patients had a median of 4 prior therapies, and
